2/13/06: ULURU Advances Development of Wound Management Portfolio. Initial Product Scheduled for Market Launch in the 4th Quarter

DALLAS--(BUSINESS WIRE)--Feb. 13, 2006--ULURU INC. ("ULURU") who has signed a definitive merger agreement with Oxford Ventures, Inc. (OTC Bulletin Board: OXFV - News) today announced plans to launch its first wound management product utilizing its hydrogel nanoparticle aggregate technology onto the United States market in the fourth quarter, 2006. In conjunction with the University of Texas Southwestern medical Center (“UTSW), we have conducted extensive preclinical studies on the biocompatibility of the hydrogel nanoparticle aggregate material and its effectiveness in wound healing. The results achieved to date indicate that the material is very biocompatible, does not elicit a foreign body response and when compared with a commercially available wound dressing significantly enhances healing.

Commenting on the results achieved in the UTSW preclinical models Dr. Spencer A. Brown, Director of Plastic Surgery Research Nancy L. and Perry Bass Advanced Wound Healing Laboratory at UTSW stated, "This material has produced unexpectedly superior results acting as both a protective barrier and producing a moist environment to accelerate wound healing. Positive results with the ULURU material were achieved with only one application in a 21 day study, while competitive products require multiple dressing changes during the same period. Reducing the number of dressing changes would not only be a significant savings to the health care provider but also improve the quality of life of the patient."

Currently the company is engaging contract manufacturers to produce the product for clinical studies and the subsequent commercial launch. ULURU plans to conduct phase IV clinical studies to support marketing of the material as a treatment of chronic wounds and burns.

Commenting on the strategic direction of ULURU, Kerry P. Gray, President and CEO of ULURU stated, "As we have previously outlined, it is our objective to establish a sales and marketing organization to market wound management and burn care products. It is planned to have in place, through the acquisition and licensing of complimentary products with established sales and marketing groups, the commercial organization to introduce this product in the fourth quarter. Given the preclinical profile of the Hydrogel Nanoparticle Aggregate material, we believe there is an exciting market opportunity for a range of wound management products utilizing this technology."

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and involve risks and uncertainties, including but not limited to statements made relating to the business prospects of ULURU Inc., the potential for ULURU Inc. to secure and maintain strategic partners, licensing revenues to be received under existing agreements and development of product candidates. These statements are subject to numerous risks and uncertainties.

(Back to 2006 Press Releases)